Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Significance: Targeting myeloid cells represents a promising strategy to augment antitumor immunity and overcome resistance to existing T cell-targeting therapies. However myeloid checkpoints that can be effectively used as immunotherapy targets are still lacking. Here, we demonstrate the therapeutic potential of targeting Siglec-7 and Siglec-9 to enhance antitumor immunity in vivo. Using an immunocompetent mouse model humanized for Siglec-7/9, we show that these receptors inhibit the endogenous antitumor immune response in a tissue-specific manner. These Siglecs also restrict the response to tumor-targeting and checkpoint-targeting antibodies, highlighting their significance in combinatorial approaches to immunotherapy. Finally, we show that Siglec-7/9 blockade can significantly reduce tumor burden in vivo, supporting the use of antibodies targeting Siglec-7/9 to therapeutically enhance antitumor immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Wiederschain, G. Y. (2009) · Biochemistry (Moscow) · doi:10.1134/s0006297909090156 · Cited by 4,083
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Varki, A. P., Cummings, R. D., Esko, J. D., Freeze, H. H., Stanley, P., Bertozzi, C. R., Hart, G. W., & Etzler, M. E. (1999) · Cited by 2,384
Siglecs and their roles in the immune system
Crocker, P. R., Paulson, J. C., & Varki, A. (2007) · Nature Reviews Immunology · doi:10.1038/nri2056 · Cited by 2,031 · cited 2×
“Based on sequence similarity, they can be divided into conserved Siglecs (Siglec-1, -2, -4, and -15), and rapidly evolving CD33-related Siglecs (CD33 or Siglec-3, Siglec-5, -6, -7, -8, -9, -10, -11, -12, -14, and -16) (17).”
BackgroundDeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis
Coffelt, S. B., Kersten, K., Doornebal, C. W., Weiden, J., Vrijland, K., Hau, C.-S., Verstegen, N. J. M., Ciampricotti, M., Hawinkels, L. J. A. C., Jonkers, J., et al. (2015) · Nature · doi:10.1038/nature14282 · Cited by 1,703
CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
Barkal, A. A., Brewer, R. E., Markovic, M., Kowarsky, M., Barkal, S. A., Zaro, B. W., Krishnan, V., Hatakeyama, J., Dorigo, O., Barkal, L. J., et al. (2019) · Nature · doi:10.1038/s41586-019-1456-0 · Cited by 1,385
Cited by
Macrophages as tools and targets in cancer therapy
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807
Mei, Y., Wang, X., Zhang, J., Liu, D., He, J., Huang, C., Liao, J., Wang, Y., Feng, Y., Li, H., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00598-9 · Cited by 224
Timperi, E., Croizer, H., Khantakova, D., Rana, M., Molgora, M., Guerriero, J. L., Mechta-Grigoriou, F., & Romano, E. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1690 · Cited by 49
The intriguing roles of Siglec family members in the tumor microenvironment
Jiang, K.-Y., Qi, L.-L., Kang, F.-B., & Wang, L. (2022) · Biomarker Research · doi:10.1186/s40364-022-00369-1 · Cited by 43
“However, a study [67] demonstrated that human Siglec-7/9 and Siglec-E inhibit the endogenous antitumor immune response as well as responses to tumor-targeting and immune checkpoint-inhibiting antibodies in vivo.”
Background
Metadata
- Authors
- Ibarlucea-Benitez, I., Weitzenfeld, P., Smith, P., & Ravetch, J. V.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2021-06-21
- Volume
- 118
- Issue
- 26
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W3174289113
- Cited by
- 177
- References
- 46
- FWCI
- 8.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity. https://app.cochat.ai/papers/10.1073/pnas.2107424118
- The paper
- Ibarlucea-Benitez, I., Weitzenfeld, P., Smith, P., & Ravetch, J. V. (2021). Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2107424118
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.